Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, the SYNCHRONIZE‐JP Trial Investigators · 2026
Read Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial by Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, the SYNCHRONIZE‐JP Trial Investigators (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13341362.txt.
Description
Koutaro Yokote and colleagues laid out the SYNCHRONIZE-JP trial design in 2026 for survodutide in Japanese adults with obesity disease. Good drug therapy for obesity in Japan stays an unmet need. Survodutide, a dual glucagon and GLP-1 receptor drug, may induce larger weight loss than GLP-1 drugs alone. The report gives the design and baseline traits of trial volunteers.
SYNCHRONIZE-JP is a phase 3, multicentre, randomised, double blind trial lasting 76 weeks. It enrols adults with body mass index at least 35 plus one obesity harm or at least 27 plus two harms, after failed diet efforts. Sharing design and baseline data before results helps readers judge the coming efficacy and safety proof.
Catalog record
| CREATOR | Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, the SYNCHRONIZE‐JP Trial Investigators |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |